ReviewCancers2022
Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Case Report: Pancreatic Paraganglioma Mimicking a Well-Differentiated Neuroendocrine Tumor: The Importance of Cytokeratin Immunohistochemistry.Diagnostic cytopathology · 2026Article
- Are head and neck versus abdominal paragangliomas driven by different single nucleotide events?Journal of applied genetics · 2026Article
- Surgical management of para-aortic paragangliomas: case series of functional and non-functional tumors.International journal of surgery case reports · 2026Article
- Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.Endocrine connections · 2026Article
- Advanced pelvic paraganglioma presenting as hematuria and urinary retention with a large intravesical mass: A case report.Urology case reports · 2026Article
- Paroxysmal hypertension unmasked by a rare urethral paraganglioma.Journal of human hypertension · 2026Article
- Article
- The Role of Cortisol Secretion in Pheochromocytomas and Paragangliomas: Clinical and Perioperative Implications.The Journal of clinical endocrinology and metabolism · 2026Article
- Differences in management and outcomes between pheochromocytomas and sympathetic paragangliomas.Frontiers in endocrinology · 2026Article
- Successful surgical removal of a retroperitoneal paraganglioma in the celiac artery trifurcation in a dog.BMC veterinary research · 2025Article
- Differences in Clinical Presentation Between Pheochromocytomas and Paragangliomas.Clinical endocrinology · 2025Article
- Article
- Article
- Cytological Assessment of Adrenal Tumours: Insights From 22-Years Single Centre Experience.Clinical endocrinology · 2025Article
- Adrenal Tumors in Children and Adolescents in Sweden: A Register-Based Study Covering 15 Years.Journal of the Endocrine Society · 2025Article
- Surgical resection of a recurrent retroperitoneal paraganglioma: A case report.World journal of clinical oncology · 2025Article
- Massive pheochromocytoma causing adrenal crisis during surgery: a case report and review of the literature.Journal of medical case reports · 2025Review
- Molecular Signatures of Cancer Stemness Characterize the Correlations with Prognosis and Immune Landscape and Predict Risk Stratification in Pheochromocytomas and Paragangliomas.Bioengineering (Basel, Switzerland) · 2025Article
- Sex differences in management and outcomes in pheochromocytomas and paragangliomas.Frontiers in endocrinology · 2025Article
- Sex differences in presentation of pheochromocytoma and paraganglioma.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas and abdominal paragangliomas (PPGLs) are rare tumors arising from the adrenal medulla or the sympathetic nervous system. This review presents a practical guidance for clinicians dealing with PPGLs. The incidence of PPGLs has risen. Most cases are detected via imaging and less present with symptoms of catecholamine excess. Most PPGLs secrete catecholamines, with diffuse symptoms. Diagnosis is made by imaging and tests of catecholamines. Localized disease can be cured by surgery. PPGLs are the most heritable of all human tumors, and germline variants are found in approximately 30-50% of cases. Such variants can give information regarding the risk of developing recurrence or metastases as well as the risk of developing other tumors and may identify relatives at risk for disease. All PPGLs harbor malignant potential, and current histological and immunohistochemical algorithms can aid in the identification of indolent vs. aggressive tumors. While most patients with metastatic PPGL have slowly progressive disease, a proportion of patients present with an aggressive course, highlighting the need for more effective therapies in these cases. We conclude that PPGLs are rare but increasing in incidence and management should be guided by a multidisciplinary team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.